Sanders Tri-institutional Therapeutics Discovery Institute Inc Co Weill Cornel
Nonprofit profile at a glance
- EIN
- 463673346
- IRS 990 coverage
- 2014–2024
- Forms available
- Form 990 2024
- Location
- New York, NY, USA
- Phone
- 2123278704
- Rating
- 63
- Verdict
- SUPPORTED
- Rating confidence
- Moderate
- Sector
- Medical Research N.E.C.
Reported finances
- Revenue
- $16,577,142
- Expenses
- $16,577,142
- Assets
- $7,307,418
- Liabilities
- $7,307,418
Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
16 people listed
Executive titles in this filing
- MANUEL BACA (VICE PRESIDENT, BIOLOGICS)
- NIGEL LIVERTON PHD (VICE PRESIDENT, CHEMISTRY)
- PATRICIA AHA (VICE PRESIDENT, OPRATIONS)
- SANDRA LORBER (VICE PRESIDENT, FINANCE)
Highest reported compensation
- SELWYN VICKERS MD (BOARD MEMBER): $6,979,162 total reported compensation
- ROBERT HARRINGTON MD (BOARD MEMBER): $2,710,554 total reported compensation
- RICHARD P LIFTON MD PHD (BOARD MEMBER): $1,593,942 total reported compensation
Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
To further and improve health and the diagnosis, prevention and treatment of disease through research, generate innovative proof-of-concept studies, and advance the scientific activities of the controlling institutions. (continued on schedule o)the sanders tri-institutional therapeutics discovery institute, inc. Was organized and is operated as an independent, non-profit corporation, controlled by leading not-for-profit academic, medical and research institutions, to further and improve health and the diagnosis, prevention and treatment of disease through translational research, generate innovative proof-of-concept studies, and advance the scientific activities of the controlling institutions (memorial sloan kettering cancer center, the rockefeller university, and weill cornell medical college) faculty, fellows and students in aspects of translational research, chemistry, pharmacology, and drug discovery.
What it reported doing in 2024
The sanders tri-institutional therapeutics discovery institute, a partnership among three world-renowned scientific and medical institutions, works to more effectively develop therapeutics that arise from discoveries made in basic science labs. With a focus on early-stage drug discovery, the institute provides expertise in medicinal chemistry and compound screening, and conducts proof of concept studies needed to demonstrate that drug candidates can successfully alter the course of a disease. Specific research projects focus on alzheimers disease, sickle cell, osteoporosis, lysosomal, lipid deposits, parkinson's and basal cell carcinoma.
Operating model
- Revenue model
- Earned-program. 97% of the money available for current operations came from fees and other program revenue.
- Distribution model
- Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
SUPPORTED - A large share of available resources goes toward mission work and program spending has grown recently. A relatively small share of voting board members are independent and the filing reports few safeguards for money sent abroad.
Rating breakdown
- Financial Efficiency: 82
- Transparency & Controls: 54
- Accountability: 42
- Sustainability: 19
- Growth: 100
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 92.4%; rating input score 92
- Program expense ratio: 92.9%; rating input score 93
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 62nd percentile among comparable filings
- Pay-setting controls: 3 of 6 controls in place; rating input score 50
- Compensation committee: Missing
- Independent consultant: Missing
- Other Form 990s reviewed: Pass
- Written employment contract: Pass
- Compensation survey or study: Missing
- Board or committee approval: Pass
- Foreign activity oversight: Scored; rating input score 0
- Grant itemization coverage: Scored; rating input score 0
- Major donor itemization: Yes; rating input score 100
- Related-party transparency: Limited
Accountability
- Independent voting board: 0%; rating input score 0; 3rd percentile among comparable filings
- Governance controls: 9 of 9 controls in place; rating input score 100
- Conflict-of-interest policy: Pass
- Whistleblower policy: Pass
- Document-retention policy: Pass
- CEO compensation review process: Pass
- Other executive compensation review process: Pass
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Pass
- Independent financial-statement audit: Pass
Sustainability
- Operating margin: 0%; rating input score 31; 31st percentile among comparable filings
- Total-asset coverage ratio: 0.44; rating input score 13; 13th percentile among comparable filings
- Liabilities to assets ratio: 1; rating input score 6; 6th percentile among comparable filings
- Officer compensation ratio: 23.4%; rating input score 3; 3rd percentile among comparable filings
Growth
- Program expense growth: 6.1% per year; rating input score 100; 50th percentile among comparable filings
- Revenue growth: 6.4% per year; rating input score 100; 55th percentile among comparable filings
- Asset growth: 7.4% per year; rating input score 100; 51st percentile among comparable filings
Details
- Where the money goes: 92.4% of revenue deployed · 92.9% of spending went to programs
- Governance: 0 of 9 board members independent · 9 of 9 filing controls reported
- Programs: 2 filed program accomplishments · $15.4M in reported program spending
- Leadership: top reported pay $7M · 16 people listed · 3 of 6 pay-setting controls reported
- Highest-paid contractors: 5 contractors listed · $4.3M reported
- Consistency: 29 of 29 current checks pass
- Schedules: 7 filed schedules · includes major donors, foreign activity, and executive pay
- Filing history: 7 filing years from 2014 to 2024
- Contacts: How to reach this organization
- Money network: 6 filed money-flow records
- Related organizations: 3 filed related-organization links
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Accountability: Independent voting board scored 0/100.
- High — Transparency & Controls: Foreign activity oversight scored 0/100.
- High — Transparency & Controls: Grant itemization coverage scored 0/100.
- Moderate — Sustainability: Operating margin scored 31/100.
- High — Sustainability: Total-asset coverage ratio scored 13/100.
- High — Sustainability: Officer compensation ratio scored 3/100.
- High — Sustainability: Liabilities to assets ratio scored 6/100.